Patents
Sitemap › C07 - Organic chemistry › C07K - Peptides › C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320)
12/2005
12/08/2005WO2005116057A1 Monoclonal antibody against abca1
12/08/2005WO2005115483A1 Assay for transmissible spongiform encephalopathies
12/08/2005WO2005115477A2 Non-natural ribonuclease conjugates as cytotoxic agents
12/08/2005WO2005115461A2 Pharmaceutical composition for modulating the activity of triglyceride hydrolase
12/08/2005WO2005115459A2 Anti-viral activity of an anti-thymidine kinase monoclonal antibody
12/08/2005WO2005115458A2 Methods and compositions related to regulation of nucleo-cytoplasmic localization of e1 dna helicase in papillomaviruses
12/08/2005WO2005115457A2 Combined active and passive targeting of biologically active agents
12/08/2005WO2005115456A2 METHODS OF MODULATING THE REPRODUCTIVE ENDOCRINE SYSTEM BY MODULATION OF TNFαACTIVITY
12/08/2005WO2005115455A2 Methods and reagents for the treatment of immunoinflammatory disorders
12/08/2005WO2005115453A2 Treatment of polychondritis and mononeuritis multiplex with anti-cd20 antibodies
12/08/2005WO2005115452A2 Fcϝriib-specific antibodies and methods of use thereof
12/08/2005WO2005115419A1 USES OF BISPECIFIC ANTIBODY (Biab) COATED DENDRITIC CELLS PULSED WITH ANTIGENS
12/08/2005WO2005078075A3 Hybrid proteins of active-site serine beta-lactamase
12/08/2005WO2005076013A3 Process for screening glycoform-specific antibodies
12/08/2005WO2005058234A3 Methods and compositions relating to ccr5 antagonist, ifn-ϝ and il-13 induced inflammation
12/08/2005WO2005055810A3 Risk markers for cardiovascular disease
12/08/2005WO2005052126A3 Biologically active antibodies recognizing a cell surface molecule selectively expressed on living mouse natural type one (i) interferon producing cells
12/08/2005WO2005051662A3 Methods for detecting l-ficolin dependent activation of the lectin pathway of complement and kits therefor
12/08/2005WO2005011580A3 Compositions and methods for herpes simplex prophylaxis and treatment
12/08/2005WO2005005627A3 Applications of a new class of enzymes: sulfiredoxines.
12/08/2005WO2005000875A3 Compositions and methods comprising a ligand of chemerin receptor
12/08/2005WO2004070010A3 A method for generating high affinity antibodies
12/08/2005WO2004069173A3 Methods for modulating an inflammatory response
12/08/2005WO2004066948A3 Mapcaxs as modifiers of the apc and axin pathways and methods of use
12/08/2005WO2004050895A3 Methods and compositions for inducing apoptosis in cancer cells
12/08/2005WO2004050704A8 Therapeutic and diagnostic agents
12/08/2005WO2004005468A3 Axs gene and protein and methods related thereto
12/08/2005WO2003060148A3 Androgen regulated nucleic acid molecules and encoded proteins
12/08/2005WO2002066494A3 Identification and cloning of a novel human gene, ret16, involved in the intracellular signaling cascade
12/08/2005US20050272919 Immunoaffinity chromatography using epitope tags to polyol-responsive monoclonal antibodies
12/08/2005US20050272918 Method of treating allergy using antibody against human interleukin-5 receptor alpha chain
12/08/2005US20050272917 Methods for immunoglobulin purification
12/08/2005US20050272916 Method of modulating the activity of functional immune molecules
12/08/2005US20050272729 Cytotoxic agents comprising taxanes and their therapeutic use
12/08/2005US20050272684 Breast cancer resistance protein (BCRP) and the DNA which encodes it
12/08/2005US20050272637 Compositions and methods for modulating signaling mediated by IGF-1 receptor and erbB receptors
12/08/2005US20050272636 Treatment and diagnosis of a reproductive disorder by measuring or inhibiting interferon-gamma
12/08/2005US20050272633 Derivatives of the nf-kappab inducing enzyme, their preparation and use
12/08/2005US20050272131 Methods to make and use antibodies of improved cross-reactivity
12/08/2005US20050272128 Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
12/08/2005US20050272127 Antibody against an angiogenesis-inhibiting peptide homologous to human ChM1L chondromodulin-I (ChM-I); hybridomas; diagnostic kits; controlling angiogenesis
12/08/2005US20050272120 Compositions and methods for the diagnosis and treatment of tumor
12/08/2005US20050272119 Polypeptides having 2',5'-oligoadenylate phosphodiesterase activity, antibodies against polypeptides, polynucleotides coding for polypeptides, recombinant plasmid DNAs into which polynucleotides have been inserted; for searching for antitumor agents, viricides
12/08/2005US20050272107 Intracellular antibodies
12/08/2005US20050272094 Purified antigen for Alzheimer's disease and methods of obtaining and using same
12/08/2005US20050272091 Neisserial protein for use in diagnosis, prevention and treatment of microorganismal infection
12/08/2005US20050272077 Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
12/08/2005US20050272058 Secreted and transmembrane polypeptides and nucleic acids encoding the same
12/08/2005US20050272050 Receptor protein for identifying modulators to treat and prevent inflammatory, antherosclerotic and cancer disorders; wound healing agents
12/08/2005US20050272029 Hepatitis c viral-like particle purification
12/08/2005US20050271683 Nucleic acid sequences encoding Ostertagia ostertagi proteins and parts of such nucleic acid sequences encode an immunogenic fragment of such proteins; for use in vaccines
12/08/2005US20050271682 Administering the chimeric protein, comprising at least a first and a second polypeptide, wherein the N-terminus of the chimeric protien comprises the first polypeptide, wherein the first polypeptide comprises Borrelia burgdorferi OspC and wherein second polypeptide comprises Borrelia burgdorferi OspA
12/08/2005US20050271681 Isolated FrpB nucleic acid molecule and vaccine
12/08/2005US20050271680 Using immunogenic proteins LigA and LigB from Leptospira in development of effective vaccines and antibodies; detection of pathogenic Leptospira infection in a mammal
12/08/2005US20050271678 Diagnostic compositions containing the polypeptide conjugated to a detectable label, such as radioisotopes, enzymes, fluorescent labels, antibody conjugates, or substrates
12/08/2005US20050271677 inhibiting Flavivirus infection by inhibiting the fusion between the virion envelope and a cell membrane; E1 envelope glycoprotein of hepaciviruses and E2 envelope glycoprotein of pestivirus have previously undescribed structures, truncated class II fusion proteins
12/08/2005US20050271674 Methods and compositions for modulating the immune system of animals
12/08/2005US20050271673 Trifunctional reagent for conjugation to a biomolecule
12/08/2005US20050271671 Anthracycline-antibody conjugates
12/08/2005US20050271670 Treatments for cancer
12/08/2005US20050271669 For therapy of proliferative disease
12/08/2005US20050271668 Janus family kinases and identification of immune modulators
12/08/2005US20050271666 Regulation of human protein phosphatase IIc-like enzyme
12/08/2005US20050271665 Administering an anti-SDF-1 or anti-CXCR4 antibody or binding fragment
12/08/2005US20050271664 Antibodies for inhibiting blood coagulation and methods of use thereof
12/08/2005US20050271663 treating rheumatoid arthritis by using single domain antibody polypeptide construct that binds human TNF- alpha
12/08/2005US20050271662 Proteins, polypeptides, fusion proteins, polynucleotides, vectors, host cells, antibodies or antigen binding portions; diagnosis and treatment of canine or feline B-cell lymphoma, immune-mediated hemolytic anemia or thrombocytopenia, and systemic lupus erythematosus
12/08/2005US20050271661 Synergistic mixture with glucocorticoid receptors antagonist
12/08/2005US20050271660 Nebulization of monoclonal antibodies for treating pulmonary diseases
12/08/2005US20050271659 Novel T-cell membrane protein (TIRC7), peptides and antibodies derived therefrom and uses thereof
12/08/2005US20050271658 Preventing autoimmune disease
12/08/2005US20050271657 Intermittent treatment regime for organ failure
12/08/2005US20050271656 Methods for designing specific ion channel blockers
12/08/2005US20050271655 Nogo receptor antagonists
12/08/2005US20050271654 Antibody purification
12/08/2005US20050271653 Methods and devices for targeting a site in a mammal and for removing species from a mammal
12/08/2005US20050271652 Treatment of pathologies which escape the immune response, using optimised antibodies
12/08/2005US20050271651 Inhibition of bright function as a treatment for excessive immunoglobulin production
12/08/2005US20050271650 Method and composition for angiogenesis inhibition
12/08/2005US20050271649 Therapeutic adjuvant
12/08/2005US20050271646 Fibrin material and method for producing and using the same
12/08/2005US20050271620 Herpes simplex virus complex
12/08/2005US20050271592 Optical diagnostic and therapeutic agents and compositions
12/08/2005DE102004022435A1 Verfahren zur Herstellung löslicher MHC-Proteine Process for the preparation of soluble MHC proteins
12/08/2005CA2777821A1 Mhc molecule-binding tumor-associated peptides
12/08/2005CA2574096A1 Glycosylated immunoglobulin and immunoadhesin comprising the same
12/08/2005CA2573304A1 Methods, kits and pharmaceutical compositions for diagnosing, delaying onset of, preventing and/or treating osteoporosis
12/08/2005CA2568428A1 Ligands binding the complex of urokinase-type plasminogen activator (upa) and its receptor (upar) that inhibit downstream upar interactions: identification and use in diagnosis ortherapy
12/08/2005CA2568363A1 Natriuretic compounds, conjugates, and uses thereof
12/08/2005CA2568019A1 Assay for transmissible spongiform encephalopathies
12/08/2005CA2567814A1 Antibodies as t cell receptor mimics, methods of production and uses thereof
12/08/2005CA2566861A1 Methods and reagents for the treatment of immunoinflammatory disorders
12/08/2005CA2566498A1 Methods for treating cancer using anti-wnt2 monoclonal antibodies and sirna
12/08/2005CA2566473A1 Uses of bispecific antibody (biab) coated dendritic cells pulsed with antigens
12/08/2005CA2566355A1 Influenza virus vaccine composition and methods of use
12/08/2005CA2563314A1 Fcyriib-specific antibodies and methods of use thereof
12/08/2005CA2562243A1 Treatment of polychondritis and mononeuritis multiplex with anti-cd20 antibodies
12/08/2005CA2553826A1 Neoplasm-specific polypeptides and their uses
12/07/2005EP1602669A1 Antibody against tumor specific antigen as target
12/07/2005EP1602668A1 Monoclonal antibodies specific to VEGF receptors and uses thereof
1 ... 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 ... 1494